AP2017009788A0 - Heterobicyclic compounds and their use for the treatment of tuberculosis - Google Patents

Heterobicyclic compounds and their use for the treatment of tuberculosis

Info

Publication number
AP2017009788A0
AP2017009788A0 AP2017009788A AP2017009788A AP2017009788A0 AP 2017009788 A0 AP2017009788 A0 AP 2017009788A0 AP 2017009788 A AP2017009788 A AP 2017009788A AP 2017009788 A AP2017009788 A AP 2017009788A AP 2017009788 A0 AP2017009788 A0 AP 2017009788A0
Authority
AP
ARIPO
Prior art keywords
tuberculosis
treatment
heterobicyclic compounds
heterobicyclic
compounds
Prior art date
Application number
AP2017009788A
Other languages
English (en)
Inventor
Hiroshi Shimizu
Yoshikazu Kawano
Shunpei Ishikawa
Yukitaka Uematsu
Toshio Shinohara
Motohiro Itotani
Yoshikazu Haraguchi
Isao Takemura
Atsunori Kaneshige
Yuya Nakai
Norimitsu Hariguchi
Yohei Hayashi
Makoto Matsumoto
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54105947&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AP2017009788(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of AP2017009788A0 publication Critical patent/AP2017009788A0/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20Oxygen atoms
    • C07D215/22Oxygen atoms attached in position 2 or 4
    • C07D215/227Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • A61P31/06Antibacterial agents for tuberculosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
AP2017009788A 2014-08-28 2015-08-28 Heterobicyclic compounds and their use for the treatment of tuberculosis AP2017009788A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2014174528 2014-08-28
PCT/JP2015/004371 WO2016031255A1 (en) 2014-08-28 2015-08-28 Heterobicyclic compounds and their use for the treatment of tuberculosis

Publications (1)

Publication Number Publication Date
AP2017009788A0 true AP2017009788A0 (en) 2017-02-28

Family

ID=54105947

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2017009788A AP2017009788A0 (en) 2014-08-28 2015-08-28 Heterobicyclic compounds and their use for the treatment of tuberculosis

Country Status (29)

Country Link
US (2) US10053446B2 (enExample)
EP (1) EP3186240B9 (enExample)
JP (1) JP6625612B2 (enExample)
KR (1) KR102418413B1 (enExample)
CN (1) CN106795117B (enExample)
AP (1) AP2017009788A0 (enExample)
AR (1) AR101704A1 (enExample)
AU (1) AU2015307873B2 (enExample)
BR (1) BR112017003231B1 (enExample)
CA (1) CA2959478C (enExample)
CY (1) CY1122286T1 (enExample)
DK (1) DK3186240T3 (enExample)
EA (1) EA038414B1 (enExample)
ES (1) ES2743788T3 (enExample)
HR (1) HRP20191486T2 (enExample)
HU (1) HUE045025T2 (enExample)
IL (1) IL250484B (enExample)
LT (1) LT3186240T (enExample)
MX (1) MX2017002312A (enExample)
MY (1) MY189098A (enExample)
NZ (1) NZ729064A (enExample)
PH (1) PH12017500290B1 (enExample)
PL (1) PL3186240T3 (enExample)
PT (1) PT3186240T (enExample)
SG (1) SG11201700882XA (enExample)
SI (1) SI3186240T1 (enExample)
TW (1) TWI687409B (enExample)
WO (1) WO2016031255A1 (enExample)
ZA (1) ZA201700916B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI687409B (zh) * 2014-08-28 2020-03-11 日商大塚製藥股份有限公司 稠合雜環化合物
CN108884044B (zh) * 2016-02-26 2023-01-31 大塚制药株式会社 哌啶衍生物
CN112543757A (zh) 2018-06-15 2021-03-23 卡迪拉保健有限公司 对结核菌具有抗菌活性的缩合氮杂杂芳基化合物
JP2023085582A (ja) * 2020-05-11 2023-06-21 大塚製薬株式会社 ジヒドロキノリノン化合物の共結晶
WO2022039506A1 (ko) * 2020-08-19 2022-02-24 주식회사 미토이뮨테라퓨틱스 Mabc-r 감염에 의한 병적 염증 치료제로서의 미토콘드리아 표적 항산화제
CN116102537B (zh) * 2021-11-10 2024-10-01 四川大学 一种喹啉酮类衍生物及其制备方法和用途
CN116589448B (zh) * 2023-04-24 2025-10-28 西南交通大学 一种3,4-二氢喹啉酮衍生物及其应用
WO2025183016A1 (ja) * 2024-02-26 2025-09-04 大塚製薬株式会社 Quabodepistat含有組成物
WO2025183017A1 (ja) * 2024-02-26 2025-09-04 大塚製薬株式会社 Quabodepistat含有組成物

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2608788B2 (ja) * 1988-10-31 1997-05-14 大塚製薬 株式会社 精神分裂病治療剤
US5668127A (en) 1995-06-26 1997-09-16 Pathogenesis Corporation Nitroimidazole antibacterial compounds and methods of use thereof
AR041198A1 (es) 2002-10-11 2005-05-04 Otsuka Pharma Co Ltd Compuesto 2,3-dihidro-6-nitroimidazo[2,1-b] oxaxol, y composiciones farmaceuticas que lo contienen
GB0319150D0 (en) * 2003-08-14 2003-09-17 Glaxo Group Ltd Novel compounds
CN100497345C (zh) * 2003-10-31 2009-06-10 大塚制药株式会社 治疗结核病的2,3-二氢-6-硝基咪唑并[2,1-b]唑化合物
PL1678185T3 (pl) 2003-10-31 2009-04-30 Otsuka Pharma Co Ltd Związki 2,3-dihydro-6-nitroimidazo[2,1-B]oksazolu do leczenia gruźlicy
JP4761756B2 (ja) 2003-10-31 2011-08-31 大塚製薬株式会社 2,3−ジヒドロイミダゾ[2,1−b]オキサゾ−ル化合物
PL2502911T3 (pl) * 2004-06-24 2017-09-29 Vertex Pharma Modulatory transporterów kasety wiążącej ATP
JPWO2007099828A1 (ja) 2006-02-23 2009-07-16 塩野義製薬株式会社 環式基で置換された含窒素複素環誘導体
GB0812648D0 (en) * 2008-07-10 2008-08-20 Prosidion Ltd Compounds
WO2010045987A1 (en) * 2008-10-23 2010-04-29 Glaxo Group Limited Substituted (aza) -1-methyl-1h-quin0lin-2-0nes as antibacterials
ES2530266T3 (es) 2009-07-31 2015-02-27 Global Alliance For Tb Drug Development Análogos de nitroimidazooxazina y sus usos
EP2697232B1 (en) 2011-04-15 2016-05-18 Otsuka Pharmaceutical Co., Ltd. 6,7-dihydroimidazo[2,1-b][1,3]oxazine bactericides
TWI687409B (zh) * 2014-08-28 2020-03-11 日商大塚製藥股份有限公司 稠合雜環化合物
CN108884044B (zh) * 2016-02-26 2023-01-31 大塚制药株式会社 哌啶衍生物

Also Published As

Publication number Publication date
NZ729064A (en) 2022-09-30
US20170253576A1 (en) 2017-09-07
EA038414B1 (ru) 2021-08-25
ZA201700916B (en) 2019-06-26
US10464926B2 (en) 2019-11-05
TW201609658A (zh) 2016-03-16
WO2016031255A1 (en) 2016-03-03
ES2743788T3 (es) 2020-02-20
JP6625612B2 (ja) 2019-12-25
MX2017002312A (es) 2017-05-08
JP2017525697A (ja) 2017-09-07
EP3186240B1 (en) 2019-06-12
SG11201700882XA (en) 2017-03-30
IL250484A0 (en) 2017-03-30
EP3186240A1 (en) 2017-07-05
SI3186240T1 (sl) 2019-10-30
AU2015307873B2 (en) 2020-01-16
TWI687409B (zh) 2020-03-11
CA2959478C (en) 2023-09-26
AU2015307873A1 (en) 2017-03-09
AR101704A1 (es) 2017-01-04
CY1122286T1 (el) 2021-01-27
PH12017500290A1 (en) 2017-06-28
EP3186240B9 (en) 2019-12-04
IL250484B (en) 2020-04-30
EA201790464A1 (ru) 2017-06-30
KR102418413B1 (ko) 2022-07-06
HRP20191486T1 (hr) 2019-11-15
CN106795117B (zh) 2020-06-26
PH12017500290B1 (en) 2023-07-19
KR20170043644A (ko) 2017-04-21
PL3186240T3 (pl) 2020-03-31
US10053446B2 (en) 2018-08-21
BR112017003231B1 (pt) 2022-10-11
LT3186240T (lt) 2019-09-10
US20180312488A1 (en) 2018-11-01
HUE045025T2 (hu) 2019-12-30
MY189098A (en) 2022-01-25
PT3186240T (pt) 2019-09-06
CA2959478A1 (en) 2016-03-03
BR112017003231A2 (pt) 2017-11-28
HRP20191486T2 (hr) 2021-09-17
DK3186240T3 (da) 2019-08-26
CN106795117A (zh) 2017-05-31

Similar Documents

Publication Publication Date Title
ZA201607415B (en) Antibody-drug-conjugate and its use for the treatment of cancer
GB201403093D0 (en) Therapeutic compounds and their use
SG11201607705XA (en) Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
PL3218005T3 (pl) Związki oddziałujące z glikanami i sposoby ich zastosowania
LT3089971T (lt) Junginiai ir panaudojimo būdai
ZA201606449B (en) Triazine compound and use thereof for medical purposes
ZA201700916B (en) Heterobicyclic compounds and their use for the treatment of tuberculosis
IL249502B (en) New therapeutic uses of benzylideneguanidine derivatives for the treatment of diseases caused by structurally abnormal proteins
IL283335B (en) Dihydropyrimidine-2-one compounds and their medical use
PL3215157T3 (pl) Apilimod do stosowania w leczeniu czerniaka
ZA201606450B (en) Compounds and their methods of use
EP3145525A4 (en) Use of microperoxidases for the treatment of carboxyhemoglobinemia
GB201403697D0 (en) Compounds and methods of use
GB201418541D0 (en) Materials for use with general hyperthermia treatment
GB201410387D0 (en) Compounds and their therapeutic use
GB201403496D0 (en) Compounds and their therapeutic use
GB201417777D0 (en) Novel compounds and therapeutic uses thereof